Академический Документы
Профессиональный Документы
Культура Документы
DRUG PRODUCTS
Outline
Outline Continued
LIPOSOMES
Liposomes are colloidal, lipid vesicles consisting of one
or more self-assembled lipid bilayers enclosing a
similar number of aqueous compartments.
Lipids, such as lecithin (diacylphosphatidylcholine), are
amphiphilic molecules. Due to the bulky nonpolar part
of the molecule they do not pack into spherical micelles
in aqueous phase but rather self-assemble into bilayers
which tend to self-close at low concentrations into
spherical structures.
LIPOSOMES Contd.
Liposomes can be subcategorized into:
Small unilamellar vesicles (SUV), 25 to 100 nm in size
that consist of a single lipid
bilayer
Large unilamellar vesicles (LUV), 100 to 400 nm in size
that consist of a single lipid bilayer
Multilamellar vesicles (MLV), 200 nm to several
microns, that consist of two or more concentric
bilayers
Vesicles above 1 m are known as giant vesicles.
Liposomes
Localized and rate controlled delivery:
Improved therapeutic response
Achieve appropriate tissue or blood levels
Reduced adverse reactions
Less drug administered
Targeted drug release
Lower dosing frequency
Improved patient compliance
Simpler dosing regimens
Lower cost per dose
Utilization of otherwise un-useable compounds
Poorly soluble drugs
.
Daunorubicin
Doxil
Daunoxome Daunorubicin
Ambisome Amphotericin B
Depocyt
Cytarabine
1995
1996
1997
1999
1995
1997
8
LIPOSOME FORMULATION
LIPOSOMES
Liposomal composition determines the properties (e.g.
surface charge, rigidity and steric interactions) and the in
vitro and in vivo performance.
Both water soluble and water insoluble drugs may be
encapsulated
Processing methods affect particle size, percentage drug
entrapment, stability and release rates
10
LIPOSOME FORMULATION
Processing methods:
Extrusion, ultrasonication and
microfluidization for hydrophobic drugs and
Reversed phase and freeze-thaw for
hydrophilic drugs.
11
12
Types of Liposomes
Conventional Liposomes
- Prepared form natural neutral and anionic lipids and have nonspecific
interactions with their environment
- Relatively unstable, have low carrying capacities, and tend to be leaky
to entrapped drug substances
- May literally fall apart on contact with plasma, particularly those of high
fluidity,
- Choleterol is often added to increase plasma stability
13
Types of Liposomes
Non-conventional Liposomes
- Small sized ( 100 nm), surface modified to overcome
some of the short comings of conventional liposomes
- Modified to reduce negative charge, decrease fluidity and
cause steric hinderance to phagocytosis
- Properties altered (e.g. by incorporation of cholesterol)
- Polymerized liposomes more stable and less leaky
- Polyetheylene glycol, pegylated liposomes, avoid uptake
by the mononuclear phagocytic cells
14
TYPES OF LIPOSOMES
Target specific ligands, such as antibodies,
immunoglobulins, lectins and oligosaccharides
attached to the surface to actively target to specific
sites in the body
Targeting via particle size
Liposomes prepared with cationic and fusogenic
lipids are currently being utilized in gene therapy to
deliver DNA into target cells
Burgess, June 28, 2001
15
TYPES OF LIPOSOMES
Highly reactive liposomes - readily undergo phase
transition in particular situation
sensitive to pH, ions, heat and light
For example, pH-sensitive liposomes can undergo phase
transition in acidic conditions resulting in increased
membrane fluidity and loss of encapsulated materials
16
Particle size
Method of manufacture
Lipid types
Phase transition temperature
Polymerization
Interfacial charge
Steric stabilization
Sterilization
17
18
19
LIPOSOME CHARACTERIZATION
StabilIty
Drug
Lipids
Liposome
20
STERILITY
Terminal sterilization?
Aseptic processing
Must consider both internal and
external sterility
21
STABILITY
Active
Inactives (especially the lipids)
Liposome as a whole need
Any change in particle size can affect targeting, RES uptake,
safety and efficacy.
In vivo stability of whole liposome is particularly important for
targeted liposomes, since they should remain stable in the
plasma without loss of contents until uptake at the target site.
22
LIPOSOME DESTABILIZATION
Protein binding
Membrane fusion
23
24
25
26
27
28
29
Batch to batch
Manufacturing process changes
Substantiation of label claims
Evaluation of potential dose dumping
Assessment of in vivo stability
30
31
32
Solvents
pH
Temperature
Agitation
Enzymes
Cell culture
Sink conditions
Volume
Sampling interval
33
34
In Vivo Factors
Delivery System Independent (Type I)
Barriers to drug diffusion: fluid viscosity,
tissue barriers (e.g. connective tissue)
Drug partitioning at the site
Available volume at the site
Motion at Site
35
In Vivo Data
Systemic delivery, then plasma levels
may be suitable
Localized delivery, plasma levels will be
36
In Vivo Data
Use animal model to help design in vitro test
Establish relationship between in vitro data and
animal in vivo data
37
38